https://www.selleckchem.com/pr....oducts/cp21r7-cp21.h
To adapt the management of prostate malignancy in response to the COVID-19 pandemic. In according to the recommendations of the European Association of Urology, we have developed practical additional document on the treatment of prostate cancer. Low-Risk Group Watchful Waiting should be offered to patients 75 years old, with a limited life expectancy and unfit for local treatment. In Active Surveillance (AS) patients re-biopsy, PSA evaluation and visits should be deferred for up to 6 months, preferring non-invasive multiparametr
Like
Comment
Share
